BSI-093
/ Biosion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
BSI-093, a best-in-class anti-BTN3A monoclonal antibody for cancer immunotherapy by activation of Vg9Vd2 T cells
(AACR 2024)
- "BSI-093 demonstrates potential best-in-class biophysical properties and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies."
IO biomarker • Hematological Malignancies • Oncology • BTN3A1 • BTN3A2
1 to 1
Of
1
Go to page
1